医学
剪辑
上消化道出血
外科
临床终点
随机对照试验
内窥镜检查
作者
Benjamin Meier,Andreas Wannhoff,U Denzer,P. Stathopoulos,Brigitte Schumacher,David Albers,Albrecht Hoffmeister,Jürgen Feisthammel,Benjamin Walter,Alexander Meining,Edris Wedi,Markus Zachäus,Tilman Pickartz,Armin Küllmer,Arthur Schmidt,Karel Caca
出处
期刊:Gut
[BMJ]
日期:2022-03-23
卷期号:71 (7): 1251-1258
被引量:47
标识
DOI:10.1136/gutjnl-2021-325300
摘要
Acute non-variceal upper gastrointestinal bleeding (NVUGIB) is managed by standard endoscopic combination therapy, but a few cases remain difficult and carry a high risk of persistent or recurrent bleeding. The aim of our study was to compare first-line over-the-scope-clips (OTSC) therapy with standard endoscopic treatment in these selected patients.We conducted a prospective, randomised, controlled, multicentre study (NCT03331224). Patients with endoscopic evidence of acute NVUGIB and high risk of rebleeding (defined as complete Rockall Score ≥7) were included. Primary endpoint was clinical success defined as successful endoscopic haemostasis without evidence of recurrent bleeding.246 patients were screened and 100 patients were finally randomised (mean of 5 cases/centre and year; 70% male, 30% female, mean age 78 years; OTSC group n=48, standard group n=52). All but one case in the standard group were treated with conventional clips. Clinical success was 91.7% (n=44) in the OTSC group compared with 73.1% (n=38) in the ST group (p=0.019), with persistent bleeding occurring in 0 vs 6 in the OTSC versus standard group (p=0.027), all of the latter being successfully managed by rescue therapy with OTSC. Recurrent bleeding was observed in four patients (8.3%) in the OTSC group and in eight patients (15.4%) in the standard group (p=0.362).OTSC therapy appears to be superior to standard treatment with clips when used by trained physicians for selected cases of primary therapy of NVUGIB with high risk of rebleeding. Further studies are necessary with regards to patient selection to identify subgroups benefiting most from OTSC haemostasis.NCT03331224.
科研通智能强力驱动
Strongly Powered by AbleSci AI